How to buy OncoCyte Corporation stock | $3.34

OncoCyte Corporation is a biotechnology business based in the US. OncoCyte Corporation shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. OncoCyte Corporation employs 51 staff and has a trailing 12-month revenue of around 0.00.

OncoCyte Corporation stock price (NASDAQ: OCX)

Use our graph to track the performance of OCX stocks over time.

OncoCyte Corporation shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$3.34
52-week range	$1.41 - $6.57
50-day moving average	$3.75
200-day moving average	$4.64
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.36

Buy OncoCyte Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy OncoCyte Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

OncoCyte Corporation price performance over time

Historical closes compared with the close of $3.34 from 2021-10-20

1 week (2021-10-14)	-2.62%
1 month (2021-09-21)	-13.70%
3 months (2021-07-21)	-40.04%
6 months (2021-04-21)	-24.77%

1 year (2020-10-21)	110.06%
2 years (2019-10-21)	102.42%
3 years (2018-10-19)	78.61%
5 years (2016-10-21)	4.3

OncoCyte Corporation financials

Revenue TTM	$4.2 million
Gross profit TTM	$-639,000
Return on assets TTM	-18.06%
Return on equity TTM	-38.67%
Profit margin	0%
Book value	$1.14
Market capitalisation	$315 million

TTM: trailing 12 months

Shorting OncoCyte Corporation shares

There are currently 2.3 million OncoCyte Corporation shares held short by investors – that's known as OncoCyte Corporation's "short interest". This figure is 7.8% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting OncoCyte Corporation shares can be evaluated.

OncoCyte Corporation's "short interest ratio" (SIR)

OncoCyte Corporation's "short interest ratio" (SIR) is the quantity of OncoCyte Corporation shares currently shorted divided by the average quantity of OncoCyte Corporation shares traded daily (recently around 499132.17391304). OncoCyte Corporation's SIR currently stands at 4.6. In other words for every 100,000 OncoCyte Corporation shares traded daily on the market, roughly 4600 shares are currently held short.

However OncoCyte Corporation's short interest can also be evaluated against the total number of OncoCyte Corporation shares, or, against the total number of tradable OncoCyte Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OncoCyte Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 OncoCyte Corporation shares in existence, roughly 20 shares are currently held short) or 0.0433% of the tradable shares (for every 100,000 tradable OncoCyte Corporation shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against OncoCyte Corporation.

Find out more about how you can short OncoCyte Corporation stock.

OncoCyte Corporation share dividends

We're not expecting OncoCyte Corporation to pay a dividend over the next 12 months.

OncoCyte Corporation share price volatility

Over the last 12 months, OncoCyte Corporation's shares have ranged in value from as little as $1.41 up to $6.57. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte Corporation's is 1.9116. This would suggest that OncoCyte Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

OncoCyte Corporation overview

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California. .

Frequently asked questions

What percentage of OncoCyte Corporation is owned by insiders or institutions?
Currently 10.329% of OncoCyte Corporation shares are held by insiders and 63.54% by institutions. How many people work for OncoCyte Corporation?
Latest data suggests 51 work at OncoCyte Corporation. When does the fiscal year end for OncoCyte Corporation?
OncoCyte Corporation's fiscal year ends in December. Where is OncoCyte Corporation based?
OncoCyte Corporation's address is: 15 Cushing, Irvine, CA, United States, 92618 What is OncoCyte Corporation's ISIN number?
OncoCyte Corporation's international securities identification number is: US68235C1071 What is OncoCyte Corporation's CUSIP number?
OncoCyte Corporation's Committee on Uniform Securities Identification Procedures number is: 68235C107